Pedmarqsi Cancer Drug Recalled Over Particle Contamination
An Austrian pharmaceutical recall for Pedmarqsi 80 mg/ml infusion solution was published on October 19, 2026, due to a potential particulate contamination in the drug supply.
-
Key Clinical Takeaways:
- Pedmarqsi contains sodium thiosulfate and is administered to lower the risk of cisplatin-induced hearing loss in pediatric cancer patients.
- The regulatory notice indicates a potential quality defect, though it does not confirm that all batches are affected or that patient injuries have occurred.
- Treatment centers must adhere to recall instructions, and authorities emphasize that families should not independently alter active cancer treatment plans.
Regulatory Notice on Pedmarqsi Infusion Solution
The official notification regarding Pedmarqsi 80 mg/ml infusion solution applies specifically to the Austrian market. The regulatory filing points to a potential defect involving particle contamination within the product supply. Intravenous medications are subject to stringent purity and quality manufacturing requirements, necessitating immediate investigation and inventory isolation when particulate matter is identified.
Clinical Indications for Sodium Thiosulfate
Pedmarqsi utilizes sodium thiosulfate as its active pharmaceutical ingredient. The intravenous solution is prescribed under specific clinical protocols to mitigate ototoxicity—specifically the risk of permanent hearing impairment—caused by cisplatin chemotherapy in children and adolescents undergoing oncology care. Maintaining sterile, particle-free solutions is vital for this patient demographic, given their heightened vulnerability during intensive cancer therapies.
Scope of the Quality Defect and Patient Guidance
While the regulatory alert mandates an official product recall for affected stock, the filing does not establish that every package of Pedmarqsi is compromised, nor does it document any adverse health events resulting from the potential contamination. Healthcare facilities managing pediatric oncology patients are instructed to review current inventory against the recalled batch details and coordinate with suppliers to maintain uninterrupted therapeutic schedules. Medical authorities advise parents and caregivers against making independent modifications to prescribed cancer regimens.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.